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ABSTRACT 
The objectives of this study were to compare the clinical effects and glycemia induced by medetomidine and 
xylazine in healthy cats and to demonstrate the reversal of the effects by atipamezole. A prospective blinded 
randomized experimental trial was used with twenty-four healthy adult cats. The animals were allocated into 
4 groups of 6 animals each to receive by intramuscular route (IM): Group M (medetomidine - 50 μg/ kg); 
Group X (xylazine - 1.1 mg/kg); Group MA (medetomidine - 50 μg/kg and 60 minutes later atipamezole - 0.2 
mg/kg); Group XA (xylazine - 1.1 mg/kg and 60 minutes later atipamezole - 0.2 mg/kg). Rectal temperature, 
respiratory  rate,  heart  rate,  systolic  arterial  pressure,  electrocardiogram,  intraocular  pressure,  degree  of 
sedation  were measured at 0, 30, 60, 120 and 180 minutes, and the serum glucose concentration  was 
measured at 0, 60, 120 and 180 minutes. The xylazine at a dose of 1.1 mg/kg and medetomidine at a dose 
of 50 μg/kg (both intramuscular) induced hypothermia, decreased heart rate, respiration and blood pressure 
and also 1st-degree A-V block in some cats, but it did not interfere significantly with intraocular pressure. The 
medetomidine induced a more pronounced hypothermia, sedation and hyperglycemia than xylazine in cats. 
The atipamezole was an excellent antagonist of the effects induced by medetomidine and xylazine in cats. 
Also, it did not interfere with the intraocular pressure values.  
Keywords: medetomidine; xylazine; atipamezole; cats. 
 
ESTUDO COMPARATIVO DOS EFEITOS DA MEDETOMIDINA E XILAZINA EM 
GATOS E REVERSÃO COM ATIPAMEZOLE  
 
 
 
RESUMO 
Os  objetivos  deste  estudo  foram  comparar  os  efeitos  clínicos  e  sobre  a  glicemia  induzidos  pela 
medetomidina e xilazina em gatos saudáveis e demonstrar a reversão destes efeitos pelo atipamezole. Um 
estudo prospectivo cego randomizado foi usado com vinte e quatro gatos adultos saudáveis. Os animais 
foram  alocados  em  4  grupos  de  6  animais  cada  para  receber  por  via  intramuscular  (IM):  Grupo  M 
(medetomidine - 50  μg/kg; Grupo X (xylazine – 1,1 mg/kg); Grupo o MA (medetomidine - 50 μg/kg e 60 
minutos após atipamezole - 0.2 mg/kg); Grupo XA (xylazine – 1,1 mg/kg e 60 minutos após atipamezole – 
0,2  mg/kg).  Temperatura  retal,  freqüência  respiratória,  freqüência  cardíaca,  pressão  arterial  sistólica, 
eletrocardiograma, pressão intraocular, grau de sedação, foram medidos a 0, 30, 60, 120 e 180 minutos, e a 
concentração de glicose sérica medido a 0, 60, 120 e 180 minutos.  A xilazina a uma dose de 1,1 mg/kg e 
medetomidina  a  uma  dose  de  50    μg/kg  (ambos  por  via  intramuscular)  induziu  hipotermia,  freqüência 
cardíaca, respiração e pressão arterial sanguínea diminuída e também bloqueio atrioventricular de 1
0 grau 
em alguns gatos, mas não interferiu significativamente com pressão intraocular. A medetomidina induziu 
hipotermia,  sedação  e  hiperglicemia  mais  pronunciada  quando  comparada  a  xilazina  em  gatos.  O 
atipamezole  foi  um  excelente  antagonista  dos  efeitos  induzidos  por  medetomidina  e  xilazina  em  gatos. 
Também, não interferiu com os valores de pressão intraocular. 
Palavras-chave: medetomidina; xilazina; atipamezole; gatos.  
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INTRODUCTION  
         The  α2  agonists  activate  the  central  α2 
receptors,  decreasing  the  release  of  dopamine 
and norepinephrine; inducing sedation, analgesia, 
mydriasis,  bradycardia,  hypothermia,  transient 
hyperglycemia,  polyuria,  vomiting  and  intestinal 
impaction (MAZE; TRANQUILLI, 1991; RUFFOLO 
et al., 1994; SINCLAIR, 2003). They can also act 
on α1 receptors (SINCLAIR, 2003)
 stimulating the 
sympathetic adrenergic α1 post-receptors located 
in  the  walls  of  arteries  and  veins  causes  initial 
hypertension followed by hypotension (RUFFOLO 
et al.,1994).    
In  veterinary  medicine,  the  first  agonist  to 
be  used  was  xylazine,  followed  by  romifidine, 
detomidine,  medetomidine  and  more  recently 
dexmedetomidine  (SINCLAIR,  2003;  MURRELL; 
HELLEBREKERS,  2005;  GRANHOLM  et  al., 
2006).
  
Synthesized in 1962, xylazine is a potent α2 
agonist  and  a  weak  α1  adrenergic  agonist. 
Medetomidine is a potent α2-selective adrenergic 
agonist  and  has  a  predominant  action  in  the 
central  nervous  system.  Medetomidine  shows 
higher  α2/α1  receptor  selectivity  than  xylazine 
(VAINIO,  1989;  VIRTANEN  et  al.,  1989). 
Structurally, due to its imidazoline ring it may also 
have affinity to bind to the imidazoline receptors 
(VIRTANEN  et  al.,  1989;  MAZE;  TRANQUILLI, 
1991;  SINCLAIR,  2003).  Atipamezole  is 
considered  a  new  generation  α2-adrenergic 
antagonist  because  of  its  greater  α2-adrenergic 
selectivity  (VIRTANEN  et  al.,  1989).  This 
substance has no significant interaction with other 
types of receptors. In cats, it was proven to be a 
very potent and selective α2-adrenergic antagonist 
(VAHA-VAHE, 1990).  
The objective of this study was to compare 
the  sedative,  cardiac,  respiratory  and  endocrine 
effects  in  cats  after  the  use  of  α2-adrenergic 
agonists,  medetomidine  and  xylazine  and  the 
reversal of those effects by atipamezole.  
MATERIALS AND METHODS 
The  experiment  was  approved  by  the 
Ethical Committee of Unoeste (protocol n.016/07). 
In  total,  24  mixed-breed  adult  healthy  cats  (14 
males  and  10  females),  obtained  from  the 
UNOESTE cat facility, and with a mean age of 3 
years  and  a  mean  weight  of  3.3±5.1  kg  were 
used. After the experiment all of the cats were put 
in the pet program for adoption of the University. 
The cats were deemed healthy by full blood work 
and physical exam. One day before running the 
experiment,  the  cats  were  socially  isolated  and 
held  in  individual  stainless  steel  cages  under  a 
12:12  artificial  light-dark  cycle.  The  room 
temperature  was  about 25°C and they  were fed 
ad  libitum  with  dry  commercial  diet.  Two 
observers  (always  the  same  along  the 
experiment)  manipulated  the  cats  in  this 
acclimatization  period  (24  hours  before  the 
experiment)  to  get  familiar  with  them.  The 
information  was  blinded  on  whether  the 
experimental group the observer was evaluating.  
The  cats  were  randomly  allocated  into  4 
groups  of  6  animals  each  as  follows:  Group  M 
(medetomidine  -  Domitor
®,  Pfizer)  received  50 
μg/kg  intramuscularly  (im)  at  a  1  mg/mL 
concentration and 0.1 ml/kg in physiologic saline 
solution 0.9% (Physiologic saline solution 0.9%
®, 
Fresenius  Kabi)  60  minutes  later;  Group  X 
(xylazine - Ronpum
®, Bayer) received 1.1 mg/kg 
im at a 20 mg/mL concentration and 0.1 ml/kg im 
physiologic saline solution 0.9% 60 minutes later; 
Group  MA  (medetomidine/atipamezole  - 
Antisedan
®,  Pfizer)  received  medetomidine  at 
same  dose  and  concentration  of  Group  M  and 
atipamezole  0.2  mg/kg  im  at  a  5  mg/ml 
concentration  60  minutes  later;  Group  XA 
(xylazine/atipamezole) received xylazine at same 
dose  and  concentration  of  Group  X  and 
atipamezole  0.2  mg/kg  im  at  a  5  mg/ml 
concentration 60 minutes later.   
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The  values  of  temperature  (T), respiratory 
rate  (RR),  heart  rate  (HR),  systolic  arterial 
pressure  (SAP),  electrocardiogram  (ECG), 
intraocular pressure (IOP) and degree of sedation 
(DS) were measured at time zero (T0) before the 
administration of the α2-adrenergic agonists; and 
30,  60,  120  and  180  minutes  after  the 
administration  of  the  α2-adrenergic  agonists.  DS 
was  considered:  (0)  absent,  (1)  discreet  -  low 
ataxia  and  protective  reflexes  present,  (2) 
moderate - reduced protective reflexes and ataxia, 
and  (3)  high  -  lateral  decubitus  and  protective 
reflexes  reduced  or  absent.  Mean  interval  for 
sedation return (MISR) was considered to be the 
time  (min)  necessary  for  the  animal  to  recover 
protective  pupillary,  palpebral,  and  interdigital 
reflexes (ANDRADE et al, 2006). The animal had 
to stand  up  without ataxia after the atipamezole 
administration. The data was always assessed by 
two  observers.  Adverse  effects  as  vomiting, 
diarrhea,  sialorrhea,  diuresis,  vocalization, 
tremors, and 3rd eyelid prolapse were evaluated 
at the end of the treatments. 
Systolic arterial pressure was measured by 
an  indirect  or  non-invasive method  with  Doppler 
Ultrasonic equipment (Parks Medical-841-A). The 
transducer was placed on the palmer surface of 
the left forelimb over the common digital branch of 
the radial artery to detect blood flow, and a blood 
pressure monitoring cuff with a width 37% the limb 
circumference was placed half way between the 
elbow  and  the  carpus  (GRANDY  et  al.,  1992; 
BINNS et al., 1995; SPARKES et al., 1999). An 
electrocardiogram  of  the  cats  in  right  lateral 
recumbency  was  recorded  (Cardiotest  EK51).  A 
mean  value  of  5  consecutive  heart  beats  was 
recorded on lead II (paper speed of 50 mm/s, 1 
cm = 1  mv)  for  each  parameter.  The  cardiac 
rhythm was evaluated by occurrence of a) sinusal; 
b)  sinusal  arrhythmia;  c)  sinusal  bradycardia;  d) 
1st degree A-V block; or e) sinus arrest (TILLEY; 
GOODWIN,  2001).  For  IOP  measurements, 
applanation tonometry using a Perkins tonometer 
(Clement  Clarke)  was  completed.  There  was 
instillation of one drop of anesthetic eye drop and 
one drop of fluorescein eye drop before the exam 
(ANDRADE et al., 2009). The serum glucose was 
measured  at  0,  60,  120  and  180  minutes  after 
administration  of  the  2  agonists.  The  blood 
samples were collected by jugular puncture. 
 The variables were measured between the 
different groups and compared using an analysis 
of  variance  (ANOVA)  with  contrasts  using  the 
Tukey method. An identical procedure was used 
to compare the different times within each group. 
Variables that did not show a normal distribution 
by  the  Kolmogorov  and  Smirnov  test  were 
submitted  to  the  Kruskal-Wallis  test  for 
comparison  between  the  groups  and  the 
Friedman  test  for  comparison  between  the 
moments. In both cases, contrasts of Dunn were 
used.  A  significance  level  of  P < 0.05  was 
adopted. 
 
RESULTS  
         Both medetomidine and xylazine decreased 
temperature  significantly  from  30  to  180  min 
compared  to  the  baseline  (T0).  Medetomidine 
induced  hypothermia  more  significantly  than 
xylazine at 120 and 180 min (P < 0.05). This effect 
was  reduced  by  atipamezole,  with  temperatures 
returning close to basal values in 180 min (Table 
1). 
The 2 agonist’s administration reduced the 
respiratory  rate  from  160  min  to  180  min 
compared to the T0. However, this decreased RR 
was  abolished  in  groups  receiving  atipamezole 
(Table 1).  
Heart rate was decreased by medetomidine 
from 30 min to 120 min and by xylazine from 30 
min  to  180  min.  Atipamezole  reestablished  HR 
after  120  min  (Table  1).  Medetomidine  and 
xylazine  decreased  SAP  from  120  to  180  min  
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compared to the T0. Atipamezole was efficient in 
reversing this situation (Table 1). 
There was no statistical difference with the 
use of medetomidine, xylazine, or atipamezole in 
the IOP measured values (Table 1). Concerning 
the  variable  degree  of  sedation  (DS), 
medetomidine and xylazine induced high DS from 
30  to  60  min,  moderate  DS  for  120  min  and 
discreet  DS  at  180  min.  After  atipamezole 
administration, the DS returned to absent (Table 
2). 
Cardiac  rhythm  was  affected  by 
medetomidine at 30 min and by xylazine at 60 min 
(Table  2).  After  atipamezole  administration,  the 
cardiac  rhythm  was  normal  for  cats  (sinusal). 
Some  cats  presented  with  1st-degree  A-V  block 
during  the  experiment  (one  cat  in  group  M,  two 
cats in group MA, one cat of Group X and one cat 
in group XA). 
Regarding  the  glucose  variables,  the  2 
agonists  increased  glucose  levels  in  all  groups 
(Table 3), but this effect was more significant with 
medetomidine from 60 to 180 min. Medetomidine 
induced hyperglycemia until the end (249.7±170.4 
mg/dL),  while  xylazine  only  induced 
hyperglycemia  for  120  min  (141.0±52.3  mg/dL) 
(Table  3).  Cats  receiving  atipamezole 
reestablished these earlier levels at 120 min. 
The  mean  interval  for  sedation  return 
(MISR)  was  significantly  increased  with 
medetomidine  (123.5±410.1  min)  compared  to 
xylazine  (87.5±35.9  min)  (P < 0.05).  The  MISR 
was  drastically  reduced  by  atipamezole  in  both 
groups, and there was no significantly difference 
(P > 0.05) between group  MA (2.0±1.0 min) and 
group XA (2.5±1.2 min).  
The  other  clinical  signs  investigated  as 
vomit, sialorrhea, tremor and 3rd eyelid prolapse 
are shown in Table 4. 
 
 
 
DISCUSSION 
Cats  are  very  susceptible  to  hypothermia 
with the use of α2 adrenergic agonists (MICHELL, 
1994).  Alpha-adrenergic  agonists  induce 
hypothermia  because  they  affect  the 
thermoregulation  center  in  the  hypothalamus 
(MACDONALD; SCHEININ, 1995).  
The  decrease  in  respiratory  rate  that  may 
occur is due to the α2-adrenergic inhibition of the 
state neurons located in the ventral portion of the 
brain (RUFFOLO et al., 1994; SINCLAIR, 2003). 
At  high  doses  of  α2-adrenergic  agonists  can 
reduce  the  sensitivity  of  the  breathing  center  to 
increased  PCO2,  accentuating  breathing 
depression  (MICHELL,  1994).  In  the  experiment 
the respiratory rate in relation to the basal values, 
maintained inside of the physiologic limits for the 
species,  doesn't  tend  clinical  relevance, 
independent  of  the  administration  of  the 
atipamezole.  
Heart rate was depressed in all groups for 
30 min after administration. It was also shown that 
the  mean  heart  rate  of  animals  treated  with 
atipamezole  showed  a  relative  increase.  An 
increased  heart  rate  induced  by  α2  antagonist 
adrenergics  is  consistent  with  other  author´s 
descriptions in cats (NILSFORS; KVART, 1996). 
Some authors reported that medetomidine causes 
similar  but  more  severe  cardiopulmonary  effects 
than  xylazine  (NILSFORS;  KVART,  1996; 
PYPENDOP;  VERSTEGEN,  1998;  SINCLAIR, 
2003), but in the present experiment, the effects 
observed  in  RR,  HR  and  SAP  induced  by 
medetomidine and xylazine are very similar. The 
decrease in systolic blood pressure is due to the 
depressant effect of xylazine on the heart rate and 
contractility,  resulting  in  a  decreased  cardiac 
output  (GREENE;  THURMON,  1988; 
PADDLEFORD; HARVEY, 1999).  
Medetomidine has been shown to induce a 
higher  degree  of  sedation  than  xylazine.  This 
difference is probably due to its increased affinity  
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and  selection  of  the  central  pre-synaptic  α2-
receptors (SINCLAIR, 2003; CULLEN, 1996). The 
α2  adrenergic  agonists  depress  the  central 
nervous  system,  causing  a  reduction  in  the 
release of noradrenalin centrally and peripherally. 
Furthermore,  they  promote  sedation  and muscle 
relaxation  by  inhibition  of  interneural  medullary 
transmission (MAZE; TRANQUILLI, 1991). There 
was  rapid  reversal  of  sedation  in  the  groups 
treated  with  atipamezole.  This  was  due  to  its 
excellent  antagonist  selectivity  for  α2  receptors 
(VAHA-VAHE, 1990). 
Arrhythmias  caused  by  α2-adrenergic  are 
probably due to reduced CNS sympathetic tonus 
and  increased  parasympathetic  activity 
(PADDLEFORD;  HARVEY,  1999;  PYPENDOP; 
VERSTEGEN,  1998).  In  this  experiment,  only 
sinusal  arrhythmia  and  1st  A-V  block  were 
observed. It is important to emphasize, that in this 
study only 5 consecutives HR and ECG readings 
were  made  and  no  others  cardiovascular 
parameters  were  taken  as  longer  ECG  strips  or 
holter  monitors,  so  some  arrhythmias  might  be 
missed during all the experimental time.  
There was no effect of xylazine at a dose of 
1.1 mg/kg IM and medetomidine at a dose of 50 
μg/kg  IM  on  the  measured  values  of  the  IOP. 
These  findings  are  consistent  with  the  use  of 
medetomidine  in  dogs  (VERBRUGGEN  et  al., 
2000).  In  cats,  the  topical  use  of  medetomidine 
and xylazine decreases IOP (BURKE; POTTER, 
1986a;  BURKE;  POTTER,  1986b;  JIN  et  al., 
1991). 
 
The cats showed significant hyperglycemia 
after  medetomidine  administration  from  60  min 
until  180  min.  This  finding  is  in  agreement  with 
others  reports  (BURTON  et  al.,  1997;  KANDA; 
HIKASA,  2008)  that  hyperglycemia  induced  by 
medetomidine is greater than xylazine in cats and 
that cats are more susceptible to hyperglycemia 
induced  by  α2  adrenergic  agonists  than  dogs. 
Induction  of  hyperglycemia  occurs  through 
inhibition  of  the  secretion  of  insulin,  which  is 
mediated by α2-adrenergic receptors; specifically, 
the subtype α2D is located in the pancreatic islets 
(ANSAH  et  al.,  1998;  ABU-BASHA  et  al.,  1999; 
KANDA; HIKASA, 2008). There was a reversal of 
hyperglycemia  in  the  groups  treated  with 
atipamezole. Atipamezole is capable of reversing 
hyperglycemia induced by α2 adrenergic agonists.  
The  MISR  showed  significant  differences 
between the experimental groups. Animals treated 
with medetomidine showed a greater duration of 
sedation compared to those treated with xylazine. 
Medetomidine  and  xylazine  induced  sedation, 
analgesia and muscle relaxation dose-dependent 
and  very  significant  in  cats  (CULLEN,  1996). 
Although the difference was not significant, there 
was  a  quicker  reversal  after  administration  of 
atipamezole  in  the  MA  group  than  in  the  XA 
group. It is important to report that all the animals 
recovered  very  well  from  medetomidine  and 
xylazine  sedation,  in  spite  of  some  side  effects 
they  have  been  observed  in  the  experimental 
groups and they be described in the Table 4.  
Xylazine  at  a  dose  of  1.1  mg/kg  and 
medetomidine  at  a  dose  of  50  μg/kg  (both 
intramuscular)  did  not  interfere  significantly  with 
intraocular  pressure.  They  induced  hypothermia, 
sinusal  arrhythmia,  1st-degree  A-V  block, 
decreased  heart  rate,  respiration  and  blood 
arterial  pressure.  Medetomidine  induced 
hypothermia,  sedation  and  more  prolonged 
hyperglycemia than xylazine in cats. Atipamezole 
was an excellent antagonist of the effects induced 
by medetomidine and xylazine in cats. Also, it did 
not interfere with the measured IOP values.  
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Table 1. Means and standard deviations (Means ± SD) of the variables: temperature (T), heart rate (HR), 
respiratory rate (RR), systolic blood pressure (SBP) and intraocular pressure (IOP), according to the different 
intervals of time . 
Variable  Group  Time (minutes) 
T0  T30  T60  T120  T180 
 
 
T 
 
M  37.8±0.4 Aa  37.9±0.4 Aa  36.4±0.5 Ab  34.9±0.7 Cb  35.5±0.8 Cb 
MA  37.9±0.6 Aa  36.6±0.7 Aa  36.1±0.7 Ab  36.0±1.0 Bb  36.8±1.0 Ba 
X  37.7±0.4 Aa  37.5±0.8 Aa  36.8±0.5 Ab  36.2±0.5 Bb  36.1±1.0 Bb 
XA  38.1±0.6 Aa  37.6±0.8 Aa  36.7±0.7 Ab  36.5±1.1 Bb  37.5±0.9 Ba 
 
 
RR 
 
M  50.0±5.5 Aa  50±12.3 Aa  38.2±6.8 Ab  30.7±5.5 Ab  37.3±7.9 Ab 
MA  43.0±13.2 Aa  30.5±6.3 Ba  27.7±8.2 Bb  45.3±18.5 Aa  40.7±4.7 Aa 
X  32.7±9.6 Ba  41.3±10.0 Ba  26.3±2.7 Bb  38.7±6.4 Aa  31.0±8.2 Aa 
XA  38.7±4.7 Ba  32.7±6.9 Ba  30.0±4.9 Aa  37.3±17.5 Aa  38.7±7.8 Aa 
 
 
HR 
M  132.7±21.2Aa  112.7±23.0 Ab  115.3±20.4 Ab  113.0±14.6 Ab  145.3±22.9 Aa 
MA  132.3±27.7Aa  90.7±16.1 Bb  90.0±12.6 Bb  151.7±29.6 Bc  169.7±27.8 Bc 
X  144.0±20.4 Aa  124.0±15.0 Ab  102.0±9.7 Bb  104.7±7.8 Ab  111.0±15.0 Ab 
XA  160.7±8.2 Aa  106.7±21.7 Bb  108.3±20.0 Bb  156.7±38.8 Ba  164.0±40.2 Ba 
 
 
SAP 
 
M  162.5±23.2 Aa  173.3±36.7 Aa  163.8±30.9 Aa  149.2±23.3 Bc  145.8±19.1 Bc 
MA  172.8±24.0 Aa  170.0±19.7 Aa  160.8±26.0 Aa  187.5±30.6 Aa  170.0±14.1 Aa 
X  169.2±18.0 Aa  158.3±22.1 Aa  158.3±20.4 Aa  146.7±19.7 Bc  155.0±16.4 Bc 
XA  160.0±0.0 Aa  133.3±46.0 Bb  153.3±25.0 Aa  173.3±25.0 Aa  175.0±12.2 Aa 
 
 
IOP 
 
M  14.3±0.2 Aa  13.1±0.1 Aa  13.1±0.2 Aa  14.1±0.1 Aa  15.4±0.2 Aa 
MA  14.5±0.1 Aa  13.1±0.1 Aa  13.1±0.1 Aa  14.2±0.1 Aa  14.7±0.1 Aa 
X  15.4±0.1 Aa  14.3±0.1 Aa  14.3±0.1 Aa  13.1±0.1 Aa  14.3±0.1 Aa 
XA  15.5±0.1 Aa  15.4±0.1 Aa  15.4±0.1 Aa  15.8±0.1 Aa  15.9±0.1 Aa 
Reference values: 38.1-39.2°C (T); 20-50 mov/min (RR); 120-240 bpm (HR); 120-170 mmHg (SAP) (BISTNER et al., 2000); 13-21 
mmHg (IOP) (ANDRADE et al., 2009). 
Upper-case letters compare groups at a same time (Kruskal-Wallis test). 
Lower-case letters compare times within each group (Friedman test). 
Same letters indicate no significant difference (P > 0.05). 
The α2-adrenergic antagonists were administrated at T60 in the MA and XA groups 
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Table 2. Medians (quartiles P25;P75) of the variables degree of sedation and cardiac rhythm according to 
the different intervals of time . 
Variable  Group  Time (minutes) 
T0  T30  T60  T120  T180 
 
 
Degree of 
Sedation 
 
M  0 (0;0) Aa 
 
3 (2;3) Bb  3 (2;3) Bb  2 (1;2) Cc  1 (1;2) Dd 
MA  0 (0;0) Aa 
 
3 (2;3) Bb  3 (2;3) Bb  0 (0;0) Aa  0 (0;0) Aa 
X  0 (0;0) Aa 
 
3 (2;3) Bb  3 (2;3) Bb  2 (1;2) Cc  1 (1;1) Dd 
XA  0 (0;0) Aa 
 
3 (2;3) Bb  3 (2;3) Bb  0 (0;0) Aa  0 (0;0) Aa 
 
 
Cardiac rhythm 
M  1 (1;1) Aa 
 
2 (2;4) Bb  2 (2;2) Bb  1 (1;1) Aa  1 (1;2) Aa 
MA  1 (1;1) Aa 
 
2 (1;2) Bb  2 (1;4) Bb  1 (1;1) Aa  1 (1;2) Aa 
X  1 (1;1) Aa 
 
1 (1;1) Aa  2 (1;4) Bb  1 (1;2) Aa  1 (1;1) Aa 
XA  1 (1;1) Aa 
 
1 (1;2) Aa  2 (1;4) Bb  1 (1;1) Aa  1 (1;1) Aa 
Degree of Sedation was considered: (0) absent, (1) discreet - low ataxia and protective reflexes present, (2) moderate - less protective 
reflexes and ataxia, and (3) high - lateral decubitus and protective reflexes reduced or absent 
Cardiac rhythms: sinusal (1). sinusal arrhythmia (2). sinusal bradycardia (3). 1st-degree A-V block (4).  sinus arrest (5). Normal rhythm: 
sinusal (TILLEY and GOODWIN, 2001). 
Upper-case letters compare groups at a same time (Kruskal-Wallis test). 
Lower-case letters compare times within each group (Friedman test). 
Same letters indicate no significant difference (P > 0.05). 
The α2-adrenergic antagonists were administrated at T60 in the MA and XA groups. 
 
Table 3. Means and standard deviations (Means ± SD) of the variable glucose, according to the different 
intervals of time . 
Variable  Group  Time (minutes) 
T0  T60  T120  T180 
 
Glucose 
M  75.8±21.1 Aa  168.3±170.7Bb  223.0±108.8 Bc  249.7±170.4 Bc 
MA  73.1±9.9 Aa  137.7±57.6 Cb  91.0±30.7 Dc  66.7±8.5 Aa 
X  72.9±13.0 Aa  132.8±37.1 Cb  141.0±52.3 Cb  110.1±46.3 Cb 
XA  74.3±10.1 Aa  141.0±35.3 Cb  79.2±25.8 Aa  63.2±9.7 Aa 
Reference values: glucose (73-134 mg/dL) (KANEKO, 1997) . 
Upper-case letters compare groups at each time (Kruskal-Wallis test). 
Lower-case letters compare times within each group (Friedman test). 
Same letters indicate no significant difference (P > 0.05). 
The α2-adrenergic antagonists were administrated at T60 in the MA and XA groups. 
 
Table  4.  Number  (and  percentage)  of  cats  showing  clinical  signs  after  the  administration  of  protocol 
treatment of each experimental group. 
Groups  Vomit  Sialorrhea  Tremors  3rd Eyelid Prolapse 
M  3 
(50.0%) 
2 
(33.3%) 
0 
(0%) 
3 
(50.0%) 
MA  1 
(16.7%) 
2 
(%) 
1 
(%) 
0 
(0%) 
X  4 
(66.7%) 
3 
(50.0%) 
1 
(16.7%) 
1 
(16.7%) 
XA 
 
5 
(83.3%) 
3 
(50.0%) 
1 
(16.7%) 
0 
(0%) 
Data from 6 cats each group. 
The α2-adrenergic antagonists were administrated at T60 in the MA and XA groups 
 
 